These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
25. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid. Wu JC; Jiang HM; Yang XH; Zheng HC Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530 [TBL] [Abstract][Full Text] [Related]
26. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627 [TBL] [Abstract][Full Text] [Related]
27. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424 [TBL] [Abstract][Full Text] [Related]
28. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells. Lucianò AM; Perciballi E; Fiore M; Del Bufalo D; Tata AM Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182656 [TBL] [Abstract][Full Text] [Related]
30. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741 [TBL] [Abstract][Full Text] [Related]
31. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027 [TBL] [Abstract][Full Text] [Related]
32. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629 [TBL] [Abstract][Full Text] [Related]
33. Reactivation of silenced α-N-catenin induces retinoic acid sensitivity in neuroblastoma cells. Clark RA; Newton M; Qiao J; Lee S; Chung DH Surgery; 2021 Nov; 170(5):1546-1553. PubMed ID: 34092372 [TBL] [Abstract][Full Text] [Related]
34. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. Ridinger J; Koeneke E; Kolbinger FR; Koerholz K; Mahboobi S; Hellweg L; Gunkel N; Miller AK; Peterziel H; Schmezer P; Hamacher-Brady A; Witt O; Oehme I Sci Rep; 2018 Jul; 8(1):10039. PubMed ID: 29968769 [TBL] [Abstract][Full Text] [Related]
35. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Mueller S; Yang X; Sottero TL; Gragg A; Prasad G; Polley MY; Weiss WA; Matthay KK; Davidoff AM; DuBois SG; Haas-Kogan DA Cancer Lett; 2011 Jul; 306(2):223-9. PubMed ID: 21497989 [TBL] [Abstract][Full Text] [Related]
36. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. Bayat Mokhtari R; Baluch N; Ka Hon Tsui M; Kumar S; S Homayouni T; Aitken K; Das B; Baruchel S; Yeger H BMC Cancer; 2017 Feb; 17(1):156. PubMed ID: 28235409 [TBL] [Abstract][Full Text] [Related]
37. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585 [TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Palani CD; Beck JF; Sonnemann J Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659 [TBL] [Abstract][Full Text] [Related]
39. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963 [TBL] [Abstract][Full Text] [Related]
40. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma. Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]